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Equine herpesvirus myeloencephalitis (EHM) remains one of the most devastating manifestations of equine
herpesvirus type 1 (EHV-1) infection but our understanding of its pathogenesis remains rudimentary, partly because
of a lack of adequate experimental models. EHV-1 infection of the ocular vasculature may offer an alternative model
as EHV-1-induced chorioretinopathy appears to occur in a significant number of horses, and the pathogenesis of
EHM and ocular EHV-1 may be similar. To investigate the potential of ocular EHV-1 as a model for EHM, and to
determine the frequency of ocular EHV-1, our goal was to study: (1) Dissemination of virus following acute infection,
(2) Development and frequency of ocular lesions following infection, and (3) Utility of a GFP-expressing virus for
localization of the virus in vivo. Viral antigen could be detected following acute infection in ocular tissues and the
central nervous system (experiment 1). Furthermore, EHV-1 infection resulted in multifocal choroidal lesions in 90%
(experiment 2) and 50% (experiment 3) of experimentally infected horses, however ocular lesions did not appear
in vivo until between 3 weeks and 3 months post-infection. Taken together, the timing of the appearance of lesions
and their ophthalmoscopic features suggest that their pathogenesis may involve ischemic injury to the chorioretina
following viremic delivery of virus to the eye, mirroring the vascular events that result in EHM. In summary, we show
that the frequency of ocular EHV-1 is 50-90% following experimental infection making this model attractive for
testing future vaccines or therapeutics in an immunologically relevant age group.Introduction
Equine herpesvirus type 1 (EHV-1) infection is common
in horses throughout the world and continues to cause
significant economic losses through frequent outbreaks
of a range of diseases including epidemic respiratory dis-
ease, abortion, neonatal foal death, equine herpesvirus
myeloencephalopathy (EHM), and chorioretinopathy [1].
Primary infection with EHV-1 occurs via the respiratory
tract and is followed by a cell-associated viremia, which
is the prerequisite for infection of endothelial cells of the
CNS, the pregnant uterus, or the eye. One of the most
devastating manifestations of EHV-1 is EHM, which is
the result of an inflammatory cascade that is associated
with EHV-1 infection of the endothelial cells of the
CNS. This infection results in damage to the microvas-
culature of the CNS due to microthrombosis, and* Correspondence: husseygi@msu.edu
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reproduction in any medium, provided the orextravasation of mononuclear cells causing perivascular
cuffing and local hemorrhage [1,2].
Outbreaks of EHM are characterized by a large number
of horses affected with mild to moderate respiratory disease
and a fever, with up to 10% of infected horses developing
EHM [3]. Neurological signs appear following the onset of
viremia and include ataxia of the hind limbs that can lead
to recumbency, loss of anal tone, flaccid paralysis of the tail
and urinary incontinence often requiring euthanasia of the
affected animal. However, despite the importance of EHM,
we have a limited understanding of its pathogenesis, partly
because of the lack of reliable and relevant models. Cur-
rently the only way to reproduce EHM experimentally in a
significant proportion of animals is to perform challenge in-
fections in horses over 20 years of age [4,5] (Dr Laura
Maxwell, Oklahoma University, personal communication)
with so called EHV-1 D752 strains. This “old horse” model
can lead to clinical EHM in 50-70% of horses, but has sev-
eral disadvantages. Firstly, horses of this age likely suffer
from immunosenescence, making observations in this ageLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hussey et al. Veterinary Research 2013, 44:118 Page 2 of 15
http://www.veterinaryresearch.org/content/44/1/118group of dubious relevance to the horse population in
general, [6,7] and making the model inappropriate for
assessing immunological protection from EHM. Secondly,
the generation of clinical EHM causes severe suffering in
horses, typically leading to euthanasia and raising ethical
concerns.
Further secondary manifestations of EHV-1 include late-
term abortions and ocular disease [8], which result from in-
fection of the endothelia of the pregnant uterus or the eye,
respectively. Ocular EHV-1 may be of particular interest as
a model for studying EHM pathogenesis because there is
evidence that the vascular network of the equine ocular
fundus is physiologically and anatomically similar to that of
the CNS, with tight junctions analogous to the “blood brain
barrier” [9]. In addition, EHV-1 induced chorioretinitis may
be observed in a much larger percentage of horses than
EHM, as one can observe subclinical infection in the eye
which is not possible in the spinal cord [8]. EHV-1 associ-
ated chorioretinitis was first described in the late 1980’s in
llamas and alpacas [10,11] and then in a mare and foal dur-
ing a natural outbreak of paralytic EHV-1 infection [12]. In
1992, one of the authors showed that experimental infec-
tion with EHV-1 induced diffuse chorioretinopathies in a
significant proportion of specific pathogen free (SPF) foals
as well as endothelial infection of the ocular vascular endo-
thelium, analogous to the known initial event in the patho-
genesis of EHM where infection of spinal cord endothelial
cells precipitates neurological disease [8]. In addition, in a
series of experimental EHV-1 infections one of the authors
(Slater) observed ocular lesions in approximately 50% of in-
fected ponies (unpublished data), further supporting the
need to investigate experimental induction of EHV-1
chorioretinopathy.
Based on these observations, the goal of the current
study was to further elucidate the pathogenesis and course
of EHV-1 induced chorioretinopathy, and to determine
similarities to EHM pathogenesis. In addition, we wanted
to determine the frequency with which EHV-1 induced
chorioretinopathy occurs following experimental infection
with the aim of using endothelial infection of the eye as an
in vivo model for endothelial infection of the CNS. As a
secondary objective, we investigated the use of fluorescein
angiography (FA) in addition to classical fundus photog-
raphy (FP) for detection of acute vascular lesions and
delays in vascular filling time or leakage due to EHV-1
infection. Finally, a mutant virus expressing the enhanced
green fluorescent protein (eGFP) was generated to allow
for possible direct visualization of infected cells in the eye
by fluorescent fundus photography (FFP).
Materials and methods
Animals
For experiment 1, 10 conventionally reared, seronegative
ponies (SN < 1:32) were purchased and 8 ponies wereinfected with an Ab4 lac-Z mutant [13] designated
Ab4Δ75-LacZ in this manuscript, while 2 ponies were
infected with the parental Ab4 strain and served as con-
trols. Ponies were group-housed in an outdoor pen with
a walk-in shelter in Cambridge, UK, throughout the ex-
periment, and were fed twice a day with a diet of hay
and pelleted concentrate and ad libitum water.
For experiment 2, 12 EHV-1 seronegative horses (SN <
1:32), at an age of 9–18 months, were housed in a remote
indoor facility in Fort Collins, CO throughout the
experiment, and were fed twice a day with a diet of hay
and pelleted concentrate and ad libitum water. All horses
in this experiment were infected with EHV-1 strain Ab4.
For experiment 3, 12 EHV-1 seronegative horses (SN <
1:32), at an age of 9–18 months, were purchased and
housed in a remote indoor facility in Fort Collins, CO,
throughout the experiment. Horses were randomly
assigned to two groups of 6 horses (Ab4 and Ab4GFP)
and were fed twice a day with a diet of hay and pelleted
concentrate and ad libitum water.
All experiments were performed in accordance with
the Animal Care and Use Committee guidelines of
Cambridge University (experiment 1) or Colorado State
University (experiments 2 and 3).
Generation and in vitro characterization of viruses
The neuropathogenic EHV-1 strain Ab4, a strain that is
known to cause respiratory disease, abortions and
neurological disease upon experimental inoculation, was
used for all experiments as the parental virus [14]. In
addition, two Ab4 mutants were generated for experi-
ments 1 and 3. For experiment 1, an Ab4 mutant con-
taining a LacZ gene was generated (Ab4Δ75-LacZ). In
this virus, ORF75 was inactivated by replacing sequences
between nucleotide position 136,115 and 113,8115 with
the E. coli LacZ gene driven by the CMV IE promoter.
The generation and characterization of Ab4Δ75-LacZ was
previously described and a schematic of its genomic
organization is given in Additional file 1a [13]. For experi-
ment 3, Ab4 containing a GFP sequence inserted between
ORF1 and ORF2 (Ab4GFP) was generated by two-step
Red-mediated (en passant) recombination [15] using the
mutagenesis primers Ab4GFP_FW: 5′ CAAACGGCAAGA
AGGAGAAATAAAACGACTGTAGTACCGCGCGTTGAC
ATTGATTATTGA 3′ and Ab4GFP_RV: 5′ GAAAGGAG
TGCATGTAAAAATAAATGCGATTAACCTTTGCCATAG
AGCCCACCGCAT3 (Additional file 1b). Briefly, to
amplify the insertion cassette, a construct containing
GFP-aphAI driven by the CMV promoter was created
and used as template to yield the PCR product used for
recombination [15]. The expression of gp2 by the re-
combinant virus was restored by co-transfection of
pAb4_CMV_GFP BAC DNA and plasmid p71Ab4 into
RK-13 cells, followed by several rounds of plaque
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population [16]. Before inoculation of ponies with
Ab4GFP, replication and GFP expression of the Ab4GFP
was tested in vitro in RK-13 cells and equine dermal cells
(NBL6) grown in minimal essential medium (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10%
fetal bovine serum (FBS), 100 U/mL penicillin and
0.1 mg/mL streptomycin (Sigma-Aldrich) in three inde-
pendent experiments.
Experimental design for in vivo studies
Three separate experiments were performed in this
study and a diagram of the experimental design is
depicted in Figure 1. Experiment 1 was a pilot study in-
vestigating the pathogenesis and route of viral spread for
ocular EHV-1 as well as viral distribution in the body
during establishment of latency following intranasal in-
fection. Two groups of conventionally reared ponies
were infected with either the parental virus (Ab4), n = 2,
or the Ab4Δ75-LacZ mutant containing a LacZ con-
struct generated by Sun et al. [13], n = 8. Physical exams
were performed daily from day −2 post-infection (pi)
through day 23 pi and nasal swabs and PBMCs for de-
tection of viral nasal shedding and viremia were col-
lected on day −2 pi and every other day until day 23 pi.
In the group of ponies infected with Ab4Δ75-LacZ, oneExp. 1 (Ab4 75-LacZ), n=10 
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Figure 1 Experimental design. Sampling regimen in the EHV-1 infecti
or Ab4Δ75-LacZ (n = 8), experiment 2 consisted of horses infected with Ab
(n = 6) or Ab4GFP (n = 6). Day 0 indicated by the dotted orange line was th
daily exams/sampling, dotted black lines indicate every other day sampling
points. The X in experiments 1 and 2 indicate euthanasia and post mortem
PCR where indicated.pony each was euthanized on days 1, 2, 3, 5, 9, 12, 19
and 23 pi for post-mortem examination and detection of
LacZ expression, EHV-1 gB DNA or LAT transcript in
respiratory, lymphoid, ocular and neuronal tissues.
Based on the results in experiment 1 and previous un-
published data, a second experiment was performed in
12 horses to study frequency and ocular pathology fol-
lowing challenge infection with Ab4. For this purpose,
clinical exams were evaluated immediately prior to and
daily for 21 days following infection. Viral nasal shed-
ding and viremia were evaluated daily for 14 days follow-
ing infection, followed by every other day between days
14 and 21 pi. Serum for measurement of SN antibody ti-
ters was collected prior to infection and on days 7, 14,
21, and 28 pi. In addition, fundus exams and classical
fundus photography (FP) were performed prior to infec-
tion and on days 4, 6, 8, 10, 12, 14, 21, 38, 54, 111 pi.
Fluorescein angiography (FA) was performed prior to in-
fection and on days 10, 14, 21, 38, 54, 111 pi.
In a third experiment, to further elucidate EHV-1
pathogenesis of the endothelium of the equine ocular
fundus vascular network by fluorescent fundus photog-
raphy (FFP), a GFP-expressing virus (Ab4GFP) was engi-
neered and compared to infection with parental virus in
two groups of 6 horses. Clinical exams were evaluated
prior to infection and daily for 21 days pi. Nasal Days  10 11 12 13 14 21 23  30   38   54   60   90   111
  14 21   28 
      X 
    10       12  14   21           38     54                 111 
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on studies. Experiment 1 consisted of ponies infected with Ab4 (n = 2)
4 (n = 12), and experiment 3 consisted of horses infected with Ab4
e time point of experimental infection. Continuous black lines indicate
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Figure 2 (See legend on next page.)
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Figure 2 Body temperature, nasal shedding and viremia following experimental EHV-1 infection in experiment 3. A. Median body
temperature expressed in °C, B. Median nasal viral shedding in nasal secretions expressed as EHV-1 gB copies, C. Median viremia in PBMCs
expressed as log gB copies/106 β-actin copies. Horses infected with the parental virus strain Ab4 (n = 6): -Δ-, horses infected with Ab4GFP
(n = 6): -Ο-.
Table 1 Serum neutralization titers in horses from the




Horse Day −1 Day 7 Day 14 Day 21
1 2 64 1024 1024
2 8 64 2048 2048
3 4 128 1024 1024
4 8 64 1024 1024
5 2 32 512 512
6 2 32 256 256
7 8 32 256 1024
8 8 64 1024 2048
9 4 64 1024 1024
10 8 64 1024 1024
11 8 32 n.d. n.d.
12 32 64 1024 2048
Ab4 vs. Ab4GFP infection (Exp.3)
Horse Day −1 Day 7 Day 14 Day 21
A (Ab4GFP) 2 2 128 256
B (Ab4) 2 4 64 256
C (Ab4GFP) 2 4 128 512
D (Ab4GFP) 2 2 32 128
E (Ab4GFP) 2 4 32 256
F (Ab4GFP) 2 4 16 128
G (Ab4) 2 8 64 128
H (Ab4) 2 8 256 512
I (Ab4) 4 8 512 512
J (Ab4) 2 4 64 128
K (Ab4GFP) 2 4 128 256
L (Ab4) 4 8 128 128
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and daily for 14 days pi, in addition to every other day
between days 14 and 21 pi. Nasal swabs from all horses
were also tested for GFP expression following infection,
and GFP expression in PBMCs was evaluated on days 5,
6, 7, 8, 9 and 10 pi by flow cytometry. Serum for meas-
urement of SN antibody titers was collected prior to in-
fection and on days 7, 14, 21, and 28 pi. In addition,
ocular exams and fluorescent fundus photography (FFP)
were performed prior to infection and on days 1–14, 21,
30, 60, and 90 pi to directly detect virus expressing GFP.
Finally, fundus photography (FP) as well as fluorescein
angiography (FA) were performed prior to infection, and
on days 54, 75 and 89 pi in order to highlight retinal pig-
mented epithelial defects secondary to EHV-1-induced
chorioretinopathy (FA).
In vivo characterization of viruses
EHV-1 infections
In experiment 1, ponies in both groups were simultan-
eously infected with 5 × 107 PFU of the respective vi-
ruses in a total volume of 2 mL administered (1 mL per
nostril) via intranasal instillation as described previously
[17]. For experiments 2 and 3, horses were infected with
5 × 107 PFU of EHV-1 strain Ab4 or Ab4GFP in a total
volume of 10 ml administered via nasopharyngeal instil-
lation and an aerosol was produced by inserting a plastic
nozzle attached to a syringe into the nostrils as de-
scribed previously [18].
Clinical monitoring, blood and nasal swab collection
For all three experiments, physical exams were per-
formed by the attending veterinarian and rectal tempera-
tures and clinical signs were recorded, including nasal or
ocular discharge, coughing, malaise, inappetence and
neurological signs.
In Experiment 1, nasal mucus for detection of virus
shedding was collected by aspiration using a vacuum
pump, as previously described [19]. In Experiments 2
and 3, nasal swabs for detection of EHV-1 viral shedding
were collected using a sterile, 6-inch DACRON swab
(Fisher Scientific Inc. Pittsburgh, PA, USA) as previously
described [20]. The swab was inserted into one nostril
and then the tip was placed in 1 mL virus isolation trans-
port media (MEM with Gentamicin and Amphotericin
B).
Blood for detection of viremia was collected in all
three experiments as indicated in the experimentaldesign section and Figure 1. Blood was collected by
jugular venipuncture into heparinized tubes in all in-
stances, and PBMC were separated as previously de-
scribed [20]. In addition, in experiment 3, blood was
collected into heparin on days 5 through 10 to deter-
mine GFP expression in PBMCs. For this purpose,
PBMCs were isolated as previously described [20] and
GFP expression was evaluated using flow cytometry.
a. 
III. Eye from infected Pony
b.
Figure 3 Expression of LacZ indicating the presence of AB4Δ75-LacZ or EHV-1 gB DNA expression following experimental infection. A.
LacZ expression as indicated by X-gal positive cells representing presence of AB4Δ75-LacZ. I. Respiratory tract 24 h pi: Beta galactosidase positive
bronchial epithelial cells (black solid arrows); positive airway debris (red solid arrow); positive interstitial cells (black open arrows). A positive
mononuclear cell, located within a perivascular cuff, is shown by a red open arrow. H&E stain, magnification × 50. II. Section of submandibular
lymph node 48 h after infection with AB4Δ75-LacZ showing beta galactosidase positive mononuclear cells (black solid arrows). H&E stain,
magnification × 400. III. Section of neurosensory retina 9 days after infection with AB4Δ75-LacZ showing beta galactosidase positive endothelial
cells (black solid arrows). H&E stain, magnification × 400. IV. Section of neurosensory retina from an uninfected pony stained with X-gal and H&E
counter stain, magnification × 200. B. In situ hybridization showing transcription of the late gB gene DNA in photoreceptors of the neurosensory
retina on day 12 pi. Positive photoreceptor nuclei (black solid arrows) and a single optic nerve ganglion cell nucleus (solid red arrow) are shown.
No counter stain, magnification x 200.







Figure 4 Detection of AB4Δ75-LacZ and expression of latency associated transcripts (LAT) in trigeminal ganglionic neurons. A. LacZ
expression as indicated by X-gal positive cell nuclei representing presence of AB4Δ75-LacZ at 48 h and 72 h pi. Two ganglionic neurons with
nuclear localization of beta galactosidase activity are shown at 48 h pi (solid arrows). No counter stain, magnification × 400. At 72 h pi, one
ganglionic neuron with nuclear localization of beta galactosidase activity (black arrow) and nucleolar localization of LAT (red arrow) is shown.
Adjacent neuronal nuclei are negative by both techniques (*). No counter stain, magnification × 400. At 120 h pi, nucleolar expression of LAT only
is shown in two ganglionic neurones with nucleolar localization of LAT (red arrow). The nuclei are negative for beta galactosidase activity. Adjacent
neuronal nuclei are negative by both techniques (*). No counter stain, magnification × 400. B. No detection of LacZ expression as indicated by
X-gal positive cell nuclei or LAT expression in the trigeminal ganglion from an uninfected control pony. No counter stain, magnification × 400.
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For experiment 1, virus shedding in nasal secretions and
cell associated viremia was determined using classical
plaque and infectious center assays as described previ-
ously [19]. For experiments 2 and 3, viral DNA in nasal
swab samples or from PBMC was isolated using the
QiaAmp DNA blood mini kit, according to manufac-
turer’s instructions (Qiagen, Inc., Valencia, CA, USA).
To determine nasal virus shedding, viral DNA load was
determined by real-time PCR using primers and aspecific probe targeting glycoprotein B (gB) as previously
described [21]. β-actin was used as the cellular house-
keeping gene using primers and probe as developed
previously [22]. Viral load was expressed as the log of
EHV-1 gB DNA copies / 106 β-actin copies [20].
Nasal swabs from all 12 horses from experiment 3 on
day 2 pi were also cultured using RK-13 cells. Briefly,
250 μL of nasal swab samples were added to 90% conflu-
ent RK-13 and the virus was allowed to adhere for 2 h.
After 2 h, the virus containing media was aspirated and
Table 2 Detection of EHV-1 gB DNA by nested gB PCR in
ocular and nervous system tissues collected post mortem
following infection of ponies with Ab4Δ75-LacZ
(experiment 1).
Pony # A B C D E F G H
Tissue Day pi/euthanasia 1 2 3 5 9 12 19 23
Cornea + + - + - + + -
Aqueous - + + - + - - -
Vitreous - - - + + + - -
Iris - - - - + - - -
Choroid - - - - - + - -
Retina - - - - + + + +
Optic nerve - - - - + - + +
Olfactory lobe - - - - + + -
Cerebrum (frontal) - - - - + - - +
Cerebrum (parietal) - - - + - - + -
Cerebrum (occipital) - - - - + - - -
Cerebrum (temporal) - - - - - + + -
Choroid plexus - - - + + + - +
Diencephalon - - - - + - + +
Midbrain - - + - + + - -
Pons - - - - + + - +
Medulla - - - - + + - +
Cerebellum - - - - - + - -
Trigeminal ganglion + + + + + + + +
+ detection of EHV-1 gB DNA; - no detection of EHV-1 gB DNA.
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(Invitrogen) containing 2% FBS. Cells were incubated for
72 h and checked daily for signs of CPE and GFP expres-
sion using regular and fluorescence microscopy.
Serum neutralization titers
Serum neutralization (SN) titers for experiments 2 and 3
were determined on days −1, 7, 14 and 21 pi as previ-
ously described [23].
Necropsy and tissue collection
In experiment 1, ponies were humanely euthanized by
intravenous injection of sodium pentobarbital at
85.8 mg/kg BWT at the times indicated in the experi-
mental design section (Figure 1) and respiratory (nasal
turbinate, trachea, lung), lymphoid (submandibular, ret-
ropharyngeal, tracheobronchial and mediastinal lymph
nodes), ocular (cornea, aqueous, iris, vitreous, choroid,
retina and optic nerve) and nervous system (trigeminal
ganglion, medulla, pons, midbrain, optic nerve, forebrain
and cerebral cortex including the olfactory lobes) tissues
were collected. Samples were divided and snap frozen in
liquid nitrogen for later DNA extraction or fixed in ice-
cold 5% paraformaldehyde for 24 h before routine waxembedding and histological processing. In experiment 2,
horse 11 was euthanized following development of
EHM, and spinal cord and ocular tissues were collected
into 5% paraformaldehyde for 24 h before routine wax
embedding and histological processing as described
above.
Detection of EHV-1 gB DNA by nested PCR
In experiment 1 only, nested PCR analysis was con-
ducted on DNA extracted from frozen tissues using a
commercial kit (DNeasy mini kit, Qiagen) following the
manufacturer’s instructions. Detection of EHV-1 DNA
was carried out using a gel-based qualitative PCR
method detecting a fragment of the EHV-1 gB gene, as
previously described [24].
Histopathology, detection of LacZ expression and in situ
hybridization
In experiment 1 only, for detection of beta galactosidase ac-
tivity, 10 μm sections were cut and stained with X-gal
(5 bromo-4-chloro-3-indolyl β-D-galactoside) using stand-
ard methods [25] and then counterstained using haema-
toxylin and eosin. EHV-1 DNA (gB gene) and latency-
associated transcripts (LAT) transcripts were detected by in
situ hybridization carried out on histology sections of tis-
sues as previously described [26], using digoxigenin-labeled
DNA probes generated either from the nested PCR ampli-
con of the gB gene of EHV-1 or from the BamHI fragment
of EHV-1 to detect RNA antisense to ORF63.
Ocular fundus photography (FP) and fluorescein
angiography (FA) and fluorescent fundus photography
(FFP)
Ocular fundus exams, fundus photography (FP), and
fluorescein angiography (FA), were performed in experi-
ments 2 and 3 following sedation with detomidine (0.02-
0.04 mg/kg, i.v.) and dilation of the pupil with 2 drops of
tropicamide 1%, and phenylephrine 2% (Bausch&Lomb
Inc.,Tampa, FL, USA). For the FA, 2–3 mL of 25% Na-
fluorescein was injected into the jugular vein (2 mg/kg)
and FA of the left eye was immediately performed using
a scanning Digital Ophthalmoscope (Wild MedTec,
Switzerland) for 90 s. For detection of GFP in the eye by
FFP, the same hand-held digital fundus ophthalmoscope
and filter were used without injection of Na-fluorescein.
Because all lesions showed a similar phenotype appear-
ing as classical donut-shaped depigmented lesions with
pigmented centers (focal or multifocal bullet or shotgun
lesions) and differences were most notable in the num-
ber of lesions occurring in different horses, a scoring
system based on number of lesions per eye was imple-
mented. For this purpose, grade 1 equaled 1–3 lesions,
grade 2 equaled 4–10 lesions, and grade 3 equaled 11 or
more lesions throughout the non-tapetal fundus.
Table 3 Ocular lesions in experiment 2: Ab4 infection.
ID # Pre-CH Day 10 Day 14 Day 20 Day 38 Day 54 Day 111 New lesions post-infection
1 OS - X - - - - -
OD - X - - - - -
2 OS - X - - - 1 X *
OD - X - - - 1 X *
3 OS Walleye X X X X X X
OD Walleye X X X X X X
4 OS - X - - - 2 3 *
OD - X - - - 1 1 *
5 OS 2 X 2 X 2 3 3 *
OD - X - 1 1 X 3 *
6 OS 2 X 2 2 2 3 X *
OD 1 X 1 1 2 2 2 *
7 OS 1 X 1 1 2 2 3 *
OD 1 X 1 1 2 X 2 *
8 OS - X - - - 1 1 *
OD - X - - - - 2 *
9 OS 1 X 1 2 X 3 X *
OD - X - - - 3 X *
10 OS - X - - - 3 X *
OD - X - - - 3 X *
11 OS - (EHM) X X X X X
OD - (EHM) X X X X X
12 OS 1 X 1 X 1 1 2 *
OD - X - - - - -
OS: left eye, OD: right eye, X: no ocular exam performed, *: new lesions post-infection, -: no lesions, 1: 1–3 lesions, 2: 4–10 lesions and 3: 11 or more lesions.
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In experiment 3, unpaired t-tests with Welch correction
were used to determine differences in clinical scores, pri-
mary and secondary fever responses, nasal viral shedding
and viremia between Ab4- and Ab4GFP-infected horses
and a p-value < 0.05 was considered significant.
Results
In vitro characterization of mutant viruses
The in vitro characterization of the Ab4Δ75-LacZ is de-
scribed elsewhere [13]. Growth kinetics of Ab4 and
Ab4GFP were compared using RK-13 (Additional file 2)
and NBL6 cells (not shown). Measurement of both
intracellular and extracellular virus titers showed that
the insertion of the GFP gene did not alter in vitro
growth kinetics of Ab4GFP when compared to Ab4.
In vivo characterization of viruses
Horses infected in all three experiments developed the
classical signs of EHV-1 respiratory disease, including bi-
phasic fever, nasal and ocular discharge, depression and
coughing. Clinical signs were similar between the parentalvirus (Ab4) infected ponies and the ponies infected with
the Ab4Δ75-LacZ mutant in experiment 1, but a statis-
tical comparison was not done in this pilot experiment
because of different group sizes and the decrease in size
of the Ab4Δ75-CMV-infected group over successive time
points. There were no significant differences in experi-
ment 3 between the parental virus and the mutant virus
except for the significantly lower secondary fever re-
sponse in horses infected with Ab4GFP (p = 0.015)
(Figure 2a).
As reported above, one horse in experiment 2 (#11)
developed EHM (grade 5/5) [27] with paralysis in both
hind limbs on day 10 pi and required euthanasia. None
of the other horses in any experiment showed any
neurological disease.
Similarly, as is typical for experimental EHV-1 infec-
tion, animals in all three experiments shed virus for mul-
tiple days following experimental infection and all
horses, except for one horse in the Ab4 infection group
of experiment 3 that never showed viremia, were viremic
for a total duration of 1–7 days between days 3 and 9
following infection. Nasal shedding did not differ





Figure 5 Development of ocular lesions following infection with EHV-1 shown by fundus photography (FP). FP in 4 representative horses
from experiments 2 and 3 prior to infection, as well as 3 weeks and 3 months after infection.
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ment 1 (data not shown) or experiment 3 (Figure 2b). In
experiment 3, horses infected with the Ab4GFP virus
showed a slightly delayed onset of viremia between days
4 and 9 when compared to horses in the Ab4 infection
group that showed viremia between days 3 and 8 post-
inoculation (Figure 2c).
Expression of GFP was detected following inoculation
of RK-13 cells with nasal swabs from horses infected
with the Ab4GFP virus (data not shown). In contrast,
horses of experiment 3 that were infected with Ab4,
showed CPE only following inoculation of RK-13, but no
GFP expression was observed at any time (data not
shown). Expression of GFP in PBMCs collected from
Ab4GFP infected horses could not be detected when
counting a total of 106 cells using flow cytometry on
days 5–10 pi (data not shown).
The SN titers in all horses from experiments 2 and 3
are shown in Table 1. Prior to inoculation with EHV-1,
all horses from experiments 2 and 3 had EHV-1 SN ti-
ters below 1:32. After challenge infection, all horsesseroconverted, with titers ranging from 1:128–1:2,048 by
day 21 post-challenge.
Detection of Ab4Δ75-LacZ and LAT transcript by in situ
hybridization (experiment 1)
LacZ expression could clearly be detected in the respira-
tory tract on day 1 (airway epithelial cells, intraluminal
debris, interstitial cells and mononuclear cells associated
with perivascular cuffs) and the mononuclear cells in
lymph nodes draining the respiratory tract on days 2
and 3 pi (Additional file 3 and Figure 3a). In addition,
LacZ expression was detected in endothelial cells of the
retina and the choroid on day 9 pi (Additional file 3 and
Figure 3a), but not in the photoreceptors of the retina
(Additional file 3 and Figure 3a). In contrast, LacZ ex-
pression was detected in the nuclei of neurons of the tri-
geminal ganglion at 48 and 72 h pi, but expression was
no longer detectable by 120 h pi (Additional file 3 and
Figure 4a). Interestingly by 72 h pi, some trigeminal gan-
glionic neurons presented with LacZ expression in the
nucleus and were also positive for LAT expression in the
Figure 6 Development of ocular lesions following infection with EHV-1 as shown by fluorescent angiography (FA). FA images from 4
representative horses from experiments 2 and 3 prior to infection and 3 months after infection.
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positive neurons detectable, while some neurons were
LAT-positive (Figure 4a). No LacZ expression could be
detected at any time in the medulla, pons, tectum, teg-
mentum, rostral colliculus, lateral geniculus, optic chi-
asm, optic nerves and olfactory lobes (data not shown).
LacZ or LAT expression was also not detected in neur-
onal tissues of an uninfected control pony (Figure 4b).Detection of EHV-1 gB DNA by nested PCR and by in situ
hybridization (experiment 1)
Retinal tissues were positive for gB DNA by nested PCR
on days 9, 12, 19 and 23 pi and choroid samples were
positive on day 12 pi (Table 2). In addition, occasional
photoreceptors were positive for gB DNA by in situ
hybridization on day 12 (Figure 3b). Interestingly, while
no virus-positive cells were detected by LacZ expression
Table 4 Ocular lesions in experiment 3: Ab4 vs. Ab4GFP infection.
ID # Virus used Pre-CH Day 54 Day 75 Day 89 new lesionspi
A Ab4GFP OS - - X 1 *
OD - - X 1 *
B Ab4 OS - X 2 2 *
OD - 1 3 3 *
C Ab4GFP OS - - - 1 *
OD 1 - - 1
D Ab4GFP OS 2 - - 2
OD - - - -
E Ab4GFP OS - - - 1 *
OD - - - 1 *
F Ab4GFP OS - - X -
OD - - X -
G Ab4 OS - - X -
OD 2 - X 2
H Ab4 OS - - - -
OD - - - -
I Ab4 OS - - - 1 *
OD - - - -
J Ab4 OS - - X -
OD 1 - X 1
K Ab4GFP OS - - X -
OD 1 - X 1
L Ab4 OS - 1 X 1 *
OD 1 - X 1
OS: left eye, OD: right eye, X: no ocular exam performed, *: new lesions post-infection (pi), -: no lesions, 1: 1–3 lesions, 2: 4–10 lesions and 3: 11 or more lesions.
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not shown), EHV- gB DNA was detected in the, me-
dulla, pons, midbrain, optic nerve, forebrain and cerebral
cortex including the olfactory lobes by PCR between
days 3 and 23, but in particular on days 9, 12, 19 and 23
(Table 2). In addition EHV- gB DNA was detected in the
trigeminal ganglion at all time points studied (Table 2).
Ocular fundus exams and fluorescent angiography
In experiment 1, no ocular clinical signs were detected
and none of the ponies developed ophthalmoscopically
visible chorioretinal lesions in the short period before
euthanasia. In experiment 2, no ocular clinical signs
were detected, but nine out of 12 horses developed
ophthalmoscopically visible chorioretinal lesions be-
tween days 20 and 111 pi (Table 3, Figures 5 and 6).
These lesions were multifocal, small, and irregularly cir-
cular lesions that occurred close to the optic disc usu-
ally, but not exclusively, within the limits of the retinal
vasculature. The lesions presented as classical donut-
shaped, depigmented lesions of the chorioretina with
pigmented centers (also referred to as “focal” or“multifocal bullet” or “shotgun” lesions [8,9]). There was
no evidence of attenuation of retinal vasculature in re-
gions where lesions and retinal vessels were co-located
(Figures 5 and 6).
One of the 12 horses was a “walleye” characterized by
a lack of pigment in the retinal pigmented epithelium.
This horse and its ocular data was not considered for
the study, as detection of chorioretinal lesions of the
type previously reported for EHV-1 infection would have
been difficult in a color-dilute fundus. Horse #11 devel-
oped EHM on day 10 pi and had to be euthanized. No
ocular lesions were detected at this time by FP or FA.
While no ocular lesions were found in vivo on day 10 pi,
EHV-1 viral antigen was detected in both the eye and
the spinal cord of this horse post mortem using immu-
nohistochemistry and an EHV-1 specific antibody (data
not shown).
Fluorescent angiography delineated the lesions visible
by classical fundus photography with improved clarity
and suggested that these lesions were likely caused by
focal loss of retinal pigmented epithelium with exposure
of underlying choroid, because fluorescing choroid was
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was observed from either retinal or choroidal blood ves-
sels suggesting that there was integrity of the vascular
walls, although choroidal vessels were unlikely to be vis-
ible prior to disruption of the RPE. Fluorescent angiog-
raphy confirmed that there was no attenuation of the
retinal vasculature in eyes with chorioretinal lesions
(Figure 6).
In experiment 3, three of six horses in each group de-
veloped new ocular lesions starting approximately
3 weeks pi (Table 4). In the Ab4GFP group, no GFP-
expressing cells were detected in vivo at any point using
the scanning Digital Ophthalmoscope (Wild MedTec,
Switzerland) and a filter capable of detecting GFP
protein.
Discussion
While it has been known for more than 25 years that
EHV-1 infection leads to chorioretinopathy causing per-
manent focal or multifocal “shotgun” lesions of the chor-
ioretina in a substantial proportion of infected horses,
[8,9], this study is the first to evaluate the frequency of
ocular EHV-1 following experimental infection with a
neuropathogenic strain of EHV-1. We show in separate
experiments that between 50% and 90% of experimen-
tally infected horses develop chorioretinal lesions. Inter-
estingly, clinically-apparent acute ocular pathology was
not observed in vivo during the period of acute infection
highlighted by biphasic fever responses and viremia, and
horses showed no clinical signs of ocular disease. Specif-
ically there were no signs of corneal disease or of uveitis
and the later appearance of chorioretinal lesions was not
associated with a loss of vision or any clinical ocular
signs. However, ocular lesions developed between weeks
3 and 7 bilaterally or unilaterally and were visible both
by FP and FA. The ophthalmoscopic appearance of the
lesions did not change after first detection suggesting
that they were static, possibly representing permanent
pathological changes in the chorioretina in response to
an insult occurring following EHV-1 infection. Acute
ocular and spinal cord pathology and viral antigen could
only be detected at post mortem in the one horse that
was euthanized due to severe EHM on day 10 pi despite
the absence of ocular findings ante mortem.
Horses in our experiments were not studied beyond
the times indicated in the individual experiments and no
long-term data were collected. This type of data may
however be important to gather in future experiments,
as long-term studies evaluating progression or, alterna-
tively, resolution of ocular lesions following EHV-1 in-
fection will be important for improved assessment of
significance of ocular lesions and reliable prognosis.
Historically, chorioretinal lesions have been divided into
three categories including, focal “bullet” lesions, multifocal“shotgun” lesions and diffuse lesions [9]. Following experi-
mental EHV-1 infection, we observed both focal and multi-
focal lesions that were either unilateral or bilateral and
located in the non-tapetal fundus as donut-shaped depig-
mented lesions with pigmented centers. This type of lesion
is typically caused by endothelial damage with subsequent
ischemic injury to the chorioretina that could result from
direct infection of the vascular endothelium following
viremia [28]. The absence of acute ocular clinical signs does
not suggest ascending infection from an initial keratitis or
uveitis as potential causes of the lesions observed. However,
the appearance of lesions after the viremic phase of infec-
tion would be consistent with ischemic episodes within the
choroidal microcirculation resulting in focal death of over-
lying retinal pigment epithelium and possibly regions of the
neuroretina. Furthermore, the data from experiment 1,
although preliminary in nature, do not suggest that EHV-1
translocates to the eye by direct extension through the cen-
tral nervous system using the olfactory lobes of trigeminal
tracts as portals of entry. The data presented here provides
preliminary evidence that the pathogenesis of EHV-1-
induced chorioretinopathy may mirror the vasculopathy
seen in uterine and CNS vessels during abortion and EHM.
Therefore, it may be possible that the vascular network in
the fundus of the eye can be used to monitor EHV-1-
induced endothelial vasculopathy and serve as “a window
into the microcirculation of the infected animal”.
Taken together, the observations from our study suggest
that ocular lesions following EHV-1 infection are caused by
a focal loss of retinal pigmented epithelium (RPE) exposing
the underlying choroid. The apparent lack of attenuation of
the retinal circulation suggests that disruption to the neu-
roretina is confined to the outer layers (photoreceptors
and/or bipolar cells) in some or all of these lesions.
However, detailed histopathological examination of affected
areas of the chorioretina is required to further define the le-
sions and this work is on-going in our laboratory. The lack
of attenuation of retinal vasculature is particularly interest-
ing because the major blood supply to the neuroretina in
the horse, in contrast that in other species, is provided by
the underlying choroidal vessels whereas the retinal vascu-
lature is limited [9,29-31]. If EHV-1 induced vascular injury
in fact occurred mainly in the choroidal vasculature, it may
explain why lesions are not visible during the early stages of
pathogenesis but only become detectable ophthalmoscopi-
cally once ischemic death of the RPE leads to focal breaks,
thus exposing the underlying choroid, which happens some
time after the initial ischemic episode. Further supportive
of the interpretation that the virus reaches vascular endo-
thelia of the eye via the blood is data obtained in experi-
ment 1, which shows replicating virus, as measured by
LacZ expression, in the respiratory tract, lymphocytes as
well as the choroidal and retinal endothelium, while it is
clearly absent from CNS tissues.
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signs of EHV-1 respiratory disease and there were no
significant differences in experiments 1 or 3 between
parental viruses and mutant viruses, except for the sig-
nificantly lower secondary fever response in horses in-
fected with Ab4GFP in experiment 3. While the same
virus strain, viral dose and experimental conditions were
used for the parental virus groups in experiments 2 and
3, differences in duration of viral nasal shedding, magni-
tude of SN titers pi, and incidence of ocular lesions
could be observed between Ab4-infected groups in the
separate experiments. This implies that, in addition to
viral factors including DNA polymerase [32,33], host
and possibly environmental factors are likely to play a
substantial role in the pathogenesis of EHV-1 infection
and endotheliotropism, similar to what has been re-
ported for the risk of developing EHM [34].
The Ab4GFP-expressing virus was designed with the aim
of directly visualizing the virus in the eye during the acute
phase of infection. Despite clearly demonstrable in vitro
GFP expression following infection of equine cells, and re-
covery from the nasal secretion of virus expressing GFP,
GFP expression following Ab4GFP infection could not be
detected in the eyes of any horse at any time pi. Similarly,
PBMCs isolated daily during the phase of viremia did not
allow for detection of GFP expression at any time using dir-
ect flow cytometric analysis. Reasons for this surprising re-
sult may be technical limitations as well as numbers of cells
actually infected with virus (i.e. only 1 in 10 000 PBMCs in-
fected), as it is possible that insufficient numbers of GFP-
expressing cells were present to be detectable by fundus
photography or flow cytometry. It is also conceivable that
the localization of the virus in the choroidal vasculature,
which is hidden by the RPE, prevents visualization of GFP-
expressing cells.
The use of fluorescein angiography did not offer advan-
tages in the detection of ocular lesions compared to con-
ventional fundus photography but did provide valuable
insight into the possible pathological changes present
within lesions. The fact that no differences in filling time or
leakage of fluorescein were observed during the acute
stages of infection suggested that inflammatory processes
are unlikely to occur in the retinal circulation, which is the
only circulation that can be observed during the acute
phase of infection.
In summary, this study showed that the frequency of ocu-
lar lesions induced by experimental infection with EHV-1
occurs in a large proportion of animals (50-90%). This per-
centage is significantly higher then the incidence of natur-
ally occurring EHM or EHM frequency in experimentally
infected young or middle-aged horses. It is likely that this
increased detection of ocular endothelial infection is due to
the fact that the location and nature of the eye allows for
detection of EHV-1 chorioretinopathy in the absence ofclinical ocular disease, in contrast to the spinal cord, where
detection of subtle lesions can be clinically inapparent and
go undetected. Our study also provides evidence that the
route and pathogenesis of EHV-1 infection of the endothe-
lia of the spinal cord and the eye is similar, making the
ocular model attractive for testing future vaccines or thera-
peutics in an immunologically relevant age group. Finally,
there is evidence that EHV-1 infection primarily affects the
choroidal vasculature, which would explain why lesions are
not detectable in vivo until at later times after infection.
Further examination of naturally occurring lesions in con-
junction with EHV-1 as well as long term clinical relevance
will be critical for an understanding of EHV-1 pathogenesis
in the vascular endothelium and long-term studies may be
important in the context of accurate prognosis following
EHV-1 infection.
Additional files
Additional file 1: Generation of mutant viruses. a. Replacement of
ORF75 of EHV-1 strain Ab4 by the LacZ gene resulting in AB4Δ 75-LacZ,
see also Sun et al. [13]. b. Insertion of green fluorescent protein between
the ORF1 and ORF2 genes of EHV-1 strain Ab4 using en passant recom-
bination resulting in Ab4GFP.
Additional file 2: In vitro growth characteristics of the Ab4 WT and
ΔORF1/2 viruses. Titers were measured on RK-13 cells and represent
results of 3 repeats. Ab4 WT virus are represented as squares, Ab4GFP are
represented as diamonds. Intracellular virus titers (a) and extracellular viral
titers (b) are depicted. Data are displayed as means ± STDEV.
Additional file 3: Detection of LacZ expression in tissues collected
post mortem following infection of ponies with Ab4Δ75-LacZ
(experiment 1). For detection of beta galactosidase activity, tissues were
collected from ponies at different times as indicated in the table and
stained with X-gal. Positive LacZ expression indicates presence of virus in
the respective tissues.
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